Idrasil

Idrasil is a standardized, pharmaceutical-grade, full-spectrum cannabis tablet developed by C3 International. It is formulated to contain a consistent profile of naturally occurring phytocannabinoids, including tetrahydrocannabinol (THC), cannabidiol (CBD), and over 65 other cannabinoids extracted from cloned cannabis plants. Idrasil targets the endocannabinoid system by acting as an agonist at the Cannabinoid receptor 1 (CB1) and Cannabinoid receptor 2 (CB2). It is primarily indicated for conditions associated with Clinical EndoCannabinoid Deficiency (CECD), such as migraine, fibromyalgia, and irritable bowel syndrome, as well as for the management of chronic pain. Unlike synthetic THC products, Idrasil provides the "entourage effect" of the full cannabis plant in a precise, oral dosage form. It is manufactured in an FDA-compliant, ISO 9001 certified laboratory and is positioned as a non-addictive alternative to opioid medications.

Brand names

Idrasil